The peptides, TR-291144 and TR-290999, first synthesized at Trimeris, are distinct compounds derived from HR2 sequences of HIV. In connection with this event, Trimeris will receive a payment from Roche.
TR-291144 and TR-290999 are being developed with the specific goal of achieving durable suppression of HIV by increasing the potency of the molecules and raising their genetic barrier to the development of resistance.
Also central to the development program is increased patient convenience via simpler, more patient-friendly administration, with a target of once-weekly dosing.
“The future of these new fusion inhibitor peptide candidates is quite promising,” said Dr Nick Cammack, vice president and head of viral diseases research at Roche. “The development announced today is reflective of our continued commitment to developing new strategies to help manage patients with HIV.”
Roche and Trimeris currently market Fuzeon, the first and only fusion inhibitor available for the treatment of HIV. Its approval and launch in 2003 represented the first completely novel approach to fighting HIV – blocking viral entry into human immune cells – since 1996.